Biocon stock value fell based on the heavy debt and questionable returns from Viatris. Although, it seems to have been executed efficiently by the newer but more experienced management. I expect topline and bottomline to shoot up accordingly.
Did the shareholders benefit out of Syngene demerger? I could not find much information online in this. Did biocon shareholders get shares of Syngene? Biocon biologics demerger should be expected on similar lines and Biocon will get valued with holding company discount. Unless, Biocon decides to reward shareholders with shares of biocon biologics.
These overhangs are what has brought the share down since most investors look at future returns. I do see value but whether Mrs. Shaw and management can unlock it efficiently remains to be seen.
| Subscribe To Our Free Newsletter |
